An interventional study of Bimuno Galacto-oligo-saccharide in Healthy, sponsored by Hospital Universitari Vall d'Hebron Research Institute. Completed. Open to participants aged 18 Years to 80 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2015-12-01.
Sponsored by Hospital Universitari Vall d'Hebron Research Institute · Not applicable, Interventional, and Basic science
Non-absorbable, fermentable residues in the diet increase intestinal gas production and induce gas-related symptoms, such as flatulence, abdominal bloating and distention; however, prebiotics, which are also fermented by colonic bacteria have been shown to improve this type of symptoms. The aim is to demonstrate changes in metabolic activity of gut microbiota and colonic biomass induced by prebiotics.
Healthy subjects (n=20) will be administered a prebiotic (Galacto-oligo-saccharide; 2.8 g/d) for 3 weeks; they will also receive a standard diet during three days. The following outcomes will be measured immediately before, at the beginning and at the end of the treatment: a) number of gas evacuations during daytime for 2 days on the standard diet, by means of an event marker; b) volume of gas evacuated via a rectal tube during 4 hours after a test meal, by means of a barostat; c) microbiota composition by fecal analysis.
Hospital Universitari Vall d'Hebron Research Institute is the lead sponsor of 268 studies on the registry; 61 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Inclusion Criteria:
-
Exclusion Criteria:
Bimuno Galacto-oligo-saccharide administration 2.7 g/d x 3 weeks
Dietary Supplement: Bimuno Galacto-oligo-saccharide
Number of daily anal gas evacuations
Time frame: Change from beginning of treatment (mean of days 2 and 3) to end of treatment (mean of days 20 and 21)
Volume of anal gas evacuation
Time frame: Change from beginning of treatment (day 3) to end of treatment (day 21)
No study locations are listed for this record.
This study is completed, as verified in Nov 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hospital Universitari Vall d'Hebron Research Institute